Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.36 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.31 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1964436 | 0.97 | — | — | |
| Cyanide SCHEMBL27807941 | 0.91 | CYP3A4 (0.35) | CYP3A4ALDH1A1TSHRTDP1HPGD | |
| SCHEMBL577856 | 0.78 | — | — | |
| SCHEMBL13573831 | 0.78 | — | — | |
| Phosphine SCHEMBL28192230 | 0.75 | CES2 (0.39) | MEN1KMT2ACES2CES1TAAR1 | |
| Hydrochloric Acid SCHEMBL22263487 | 0.74 | CYP3A4 (0.41) | CYP3A4ALDH1A1TSHRTDP1HPGD | |
| Hydrochloric Acid SCHEMBL4376685 | 0.73 | CYP3A4 (0.53) | CYP3A4ALDH1A1TSHRTDP1HPGD | |
| Hydrochloric Acid SCHEMBL3152989 | 0.73 | — | — | |
| SCHEMBL601969 | 0.70 | — | — | |
| SCHEMBL59477 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115697971-A | Cyclobutyldihydroquinoline sulfonamide compound | 美国安进公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-104592128-A | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB | 2015-05-06 | — | — | CN | disclosed |
| EP-1966158-B1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | ASTRAZENECA AB (SE) | 2011-06-16 | — | — | US | disclosed |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | ASTRAZENECA AB (SE) | 2010-07-22 | — | — | US | disclosed |
| EP-2167091-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| CN-101379042-A | Substituted cinnoline derivatives as GABAA receptor modulators and methods of synthesis thereof | ASTRAZENECA AB (SE) | 2009-03-04 | — | — | CN | disclosed |
| US-20090036454-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-02-05 | — | — | US | disclosed |
| US-20090018112-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | US | disclosed |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008155573-A1 | CINNOLINE COMPOUNDS FOR USE IN THE TREATMENT OF SCHIZOPHRENIA | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | WO | disclosed |
| US-7465795-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-12-16 | — | — | US | disclosed |
| US-7425556-B2 | Compounds and uses thereof | ASTRAZENECA AB (SE) | 2008-09-16 | — | — | US | disclosed |
| EP-1966158-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | AstraZeneca AB (SE) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007073283-A1 | SUBSTITUTED CINNOLINE DERIVATIVES AS GABAA-RECEPTOR MODULATORS AND METHOD FOR THEIR SYNTHESIS | ASTRAZENECA AB (SE) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142328-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-20070142382-A1 | Compounds and Uses Thereof | ASTRAZENECA AB (SE) | 2007-06-21 | — | — | US | disclosed |
| US-4855445-A | Substituted-8-alkenyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acids | AMERICAN HOME PRODUCTS CORPORATION (US) | 1989-08-08 | — | — | US | disclosed |
| US-4822781-A | ANTIINFLAMMATORY, ANALGESIC AGENTS | AMERICAN HOME PRODUCTS (US) | 1989-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142328-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | PIK3CA 3253/4885HTR2C 17/4885HTR2B 33/4885 |
| US-20070142382-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | PIK3CA 3253/4885HTR2C 17/4885HTR2B 33/4885 |
| US-20110144331-A1 | Cinnoline Compounds for the Treatment of Anxiety, Cognitive and Mood Disorders | HTR7, HTR2C, CRH | PIK3CA 2403/4885HTR2C 2/4885HTR2B 9/4885 |
| US-20090018112-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | PIK3CA 3253/4885HTR2C 17/4885HTR2B 33/4885 |
| US-20090036454-A1 | Compounds and Uses Thereof | MAPT, BDNF, PYGB | PIK3CA 3253/4885HTR2C 17/4885HTR2B 33/4885 |
| US-20100184738-A1 | Uses of cinnoline compounds to treat schizophrenia | COMT, BACE1, CHAT | PIK3CA 4070/4885HTR2C 56/4885HTR2B 71/4885 |
| US-20080318925-A1 | Compounds and Uses Thereof - 849 | COMT, UGT1A9, BACE1 | PIK3CA 3981/4885HTR2C 472/4885HTR2B 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.